First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation Therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation Therapy
(NASDAQ: VERU) Delayed: 3.04 +0.08 (2.70%)
Previous Close $2.96    52 Week High $ 
Open $2.91    52 Week Low $ 
Day High $3.07    P/E N/A 
Day Low $2.91    EPS $ 
Volume 344,774